Sponsor

Clinical trials sponsored by Eli Lilly and Company

Active studies whose public registry record names Eli Lilly and Company as lead sponsor.

67active studies

26recruiting now

30countries represented

743largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

Atherosclerosis Cardiovascular Disease, Chronic Kidney DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina566 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07241390See eligibility →

Recruiting nowPhase 3

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

Metabolic Dysfunction-Associated Steatotic Liver DiseaseCondition

Tirzepatide, RetatrutideTreatment

Argentina, Australia563 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07165028See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07392190See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Peripheral Arterial DiseaseCondition

Orforglipron, PlaceboTreatment

Argentina, Australia161 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07223593See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, China157 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07282600See eligibility →

Recruiting nowPhase 3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Osteoarthritis, Overweight or ObesityCondition

Eloralintide, PlaceboTreatment

Argentina, Belgium152 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07353931See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

Urinary Incontinence,StressCondition

Orforglipron, PlaceboTreatment

Canada, China136 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07202884See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

Sleep Apnea, Obstructive, ObesityCondition

Eloralintide, PlaceboTreatment

Australia, Brazil115 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07369011See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 4

A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)

Psoriatic Arthritis, Overweight or ObesityCondition

TirzepatideTreatment

Puerto Rico, United States55 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06864026See eligibility →

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who Observe Ramadan Fasting

Diabetes Mellitus, Type 2, Diabetes MelletusCondition

OrforglipronTreatment

India, Saudi Arabia40 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07613307See eligibility →

Recruiting nowPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Ulcerative Colitis, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium187 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937086See eligibility →

Recruiting nowPhase 3

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

Crohn's Disease, Obesity or OverweightCondition

Mirikizumab, MirikizumabTreatment

Austria, Belgium183 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06937099See eligibility →

Recruiting nowPhase 3

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

Obesity, Weight GainCondition

Tirzepatide, PlaceboTreatment

Argentina, Australia69 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06439277See eligibility →

Recruiting nowPhase 4

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

Psoriasis, Overweight or ObesityCondition

TirzepatideTreatment

United States39 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT06857942See eligibility →

Recruiting nowPhase 1

A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4174794, LY4174794Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-01 · NCT07654972See eligibility →

Recruiting nowPhase 3

A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Belgium, Brazil117 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672549See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Singapore, United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-08-20 · NCT07738614See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 1

A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity

Overweight, ObesityCondition

Eloralintide, PlaceboTreatment

Germany, Sweden2 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07665879See eligibility →

Recruiting nowPhase 4

A Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)

ObesityCondition

Tirzepatide, Standard of CareTreatment

United Kingdom30 locations

Eli Lilly and CompanySponsor

Updated 2026-07-07 · NCT07247084See eligibility →

Opening soonPhase 1

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Obesity, OverweightCondition

LY4329090, PlaceboTreatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808073See eligibility →

Opening soonPhase 1

A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight

Obesity, OverweightCondition

Eloralintide, Combined oral contraceptiveTreatment

United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07808060See eligibility →

Opening soonPhase 1

A Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity

Diabetes Mellitus, Type 1, OverweightCondition

Tirzepatide, AcetaminophenTreatment

United States1 locations

Eli Lilly and CompanySponsor

Updated 2026-09-04 · NCT07803744See eligibility →

Opening soonPhase 3

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

Overweight, Prediabetic StateCondition

Orforglipron, PlaceboTreatment

Argentina, China179 locations

Eli Lilly and CompanySponsor

Updated 2026-08-31 · NCT07794579See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

China13 locations

Eli Lilly and CompanySponsor

Updated 2026-08-27 · NCT07790861See eligibility →

Opening soonPhase 2

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

Atherosclerosis, Cardiovascular DiseaseCondition

Clazakizumab, PlaceboTreatment

Argentina, Japan47 locations

Eli Lilly and CompanySponsor

Updated 2026-08-25 · NCT07783802See eligibility →

Opening soonPhase 3

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

Diabetes Mellitus, Type 2Condition

Orforglipron, DulaglutideTreatment

Belgium, Brazil71 locations

Eli Lilly and CompanySponsor

Updated 2026-08-19 · NCT07668336See eligibility →

Opening soonPhase 1

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Japan3 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT07765511See eligibility →

Active, not recruitingPhase 3

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)

Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)Condition

Retatrutide, PlaceboTreatment

Argentina743 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06383390See eligibility →

Active, not recruitingPhase 4

A Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity

Diabetes Mellitus, Type 2, ObesityCondition

TirzepatideTreatment

India21 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07438444See eligibility →

Active, not recruitingPhase 1

A Study of LY4064912 in Healthy Participants and With Overweight or Obesity

Overweight or Obesity, HealthyCondition

LY4064912, LY4064912Treatment

Singapore, United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-08-18 · NCT07152002See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Brazil, China138 locations

Eli Lilly and CompanySponsor

Updated 2026-08-14 · NCT05869903See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-31 · NCT06993792See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT06972459See eligibility →

Active, not recruitingPhase 1

A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

Overweight, ObesityCondition

LY4167586, PlaceboTreatment

Singapore, United States2 locations

Eli Lilly and CompanySponsor

Updated 2026-07-29 · NCT07225556See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

Type 2 DiabetesCondition

Retatrutide, PlaceboTreatment

Argentina, Brazil76 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06297603See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 1

A Study of LY3971297 in Healthy Participants

Healthy, ObesityCondition

LY3971297, PlaceboTreatment

Japan, Singapore7 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06148272See eligibility →

Active, not recruitingPhase 1

A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity

Obesity, OverweightCondition

Brenipatide, PlaceboTreatment

United States3 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT07476118See eligibility →

Active, not recruitingPhase 1

A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Insulin SensitivityCondition

Retatrutide, SemaglutideTreatment

Germany1 locations

Eli Lilly and CompanySponsor

Updated 2026-07-16 · NCT06982859See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

Tirzepatide, PlaceboTreatment

Canada, Czechia33 locations

Eli Lilly and CompanySponsor

Updated 2026-06-29 · NCT06075667See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingPhase 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening)

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China100 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948422See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1

Hypertension, Overweight or ObesityCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06948435See eligibility →

Active, not recruitingPhase 3

A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2

HypertensionCondition

Orforglipron, PlaceboTreatment

Argentina, China99 locations

Eli Lilly and CompanySponsor

Updated 2026-05-29 · NCT06952530See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight

Obesity, OverweightCondition

Bimagrumab, TirzepatideTreatment

United States12 locations

Eli Lilly and CompanySponsor

Updated 2026-05-26 · NCT06643728See eligibility →

Active, not recruitingPhase 1

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2, OverweightCondition

TirzepatideTreatment

Singapore1 locations

Eli Lilly and CompanySponsor

Updated 2026-05-19 · NCT07299084See eligibility →

Active, not recruitingPhase 3

A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight

Type 1 Diabetes, ObesityCondition

Tirzepatide, PlaceboTreatment

Argentina, Brazil146 locations

Eli Lilly and CompanySponsor

Updated 2026-05-12 · NCT06914895See eligibility →

Active, not recruitingPhase 2

A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

Overweight, ObesityCondition

Tirzepatide, PlaceboTreatment

Austria, Canada27 locations

Eli Lilly and CompanySponsor

Updated 2026-05-08 · NCT05536804See eligibility →

Active, not recruitingPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Argentina, China80 locations

Eli Lilly and CompanySponsor

Updated 2026-04-20 · NCT06972472See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

United Kingdom, United States31 locations

Eli Lilly and CompanySponsor

Updated 2026-04-17 · NCT07232719See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2Condition

Retatrutide, SemaglutideTreatment

Argentina, Canada77 locations

Eli Lilly and CompanySponsor

Updated 2026-04-13 · NCT06260722See eligibility →

This page shows the first 60 studies. Use the full search to filter all matches.

Related sponsors

Novo Nordisk A/S71 University of Colorado, Denver36 Cairo University31 Mayo Clinic29 Norwegian University of Science and Technology25

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.